Rural and Minority Health Research Center, University of South Carolina, Columbia, South Carolina; Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, South Carolina.
Rural and Minority Health Research Center, University of South Carolina, Columbia, South Carolina; Department of Health Services Policy and Management, University of South Carolina, Columbia, South Carolina.
J Am Coll Radiol. 2019 Apr;16(4 Pt B):590-595. doi: 10.1016/j.jacr.2019.01.001.
Rural populations have higher rates of smoking and both lung cancer incidence and mortality compared with their urban peers. As such, it is imperative that high-risk, rural populations have access to recommended low-dose CT (LDCT) screening, which can detect lung cancer at an earlier, more treatable stage. Data from the 2015 National Health Interview Survey, a nationally representative survey, were analyzed to assess nonmetropolitan-metropolitan and geographic differences in LDCT utilization among screening-eligible individuals. Screening uptake did not differ by nonmetropolitan vs. metropolitan status (3.72% and 3.83%, respectively). Regional uptake varied from 1.58% in the West to 10.11% in the Northeast. Additionally, nonmetropolitan populations represent a disproportionately high 23% of the screening-eligible population despite accounting for only 15% of the US population. There are two key challenges to high-quality LDCT screening experienced by rural populations: (1) geographic access to LDCT screening programs and (2) provider-patient communication. Despite the increased availability of LDCT screening centers since 2015, which is when most insurance plans began to cover the costs of screening, centers are geographically maldistributed relative to the rural-urban and regional need. Although decision aids can facilitate discussion between providers and patients regarding the risks and benefits of LDCT screening, research on the uptake and utility of these tools in rural areas is very limited. Analyses of population-based surveys and administrative and clinical data are needed to continue to surveil screening utilization, elucidate predictors of screening use, and inform shared decision-making tools and interventions for at-risk rural populations.
农村人口的吸烟率和肺癌发病率及死亡率均高于城市人口。因此,高危农村人群必须能够获得推荐的低剂量 CT(LDCT)筛查,以便在更早、更可治疗的阶段发现肺癌。对 2015 年全国健康访谈调查(一项具有全国代表性的调查)的数据进行了分析,以评估符合筛查条件的个体中,非大都市-大都市和地理差异对 LDCT 利用的影响。筛查参与率在非大都市与大都市之间没有差异(分别为 3.72%和 3.83%)。区域利用率从西部的 1.58%到东北部的 10.11%不等。此外,尽管非大都市人口仅占美国人口的 15%,但他们却占了符合筛查条件人群的 23%,这一比例不成比例地过高。农村人群在接受高质量 LDCT 筛查方面面临两个关键挑战:(1)获得 LDCT 筛查项目的地理位置,(2)医患沟通。尽管自 2015 年以来,LDCT 筛查中心的数量有所增加,大多数保险计划开始覆盖筛查费用,但与城乡和地区需求相比,中心的地理分布不均。尽管决策辅助工具可以促进提供者和患者之间关于 LDCT 筛查的风险和收益的讨论,但关于这些工具在农村地区的采用和实用性的研究非常有限。需要对基于人群的调查以及行政和临床数据进行分析,以继续监测筛查的利用情况,阐明筛查使用的预测因素,并为有风险的农村人群提供共享决策工具和干预措施。